Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19

Front Med (Lausanne). 2021 Sep 6:8:743325. doi: 10.3389/fmed.2021.743325. eCollection 2021.
No abstract available

Keywords: COVID-19; SARS-CoV-2; convalescent plasma; heterologous antibodies; hyperimmune polyclonal antibodies; monoclonal antibodies; passive immunotherapy.